IDH mutations result in down-regulation of genes involved in immune activation of cancer cells likely occurring either by a direct metabolic inhibitory effect of D2-HG or through epigenetic reprogramming by hypermethylation of promotors of immune-related genes (47). The gene discussed is IDH2; the disease is cancer.